AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma
Gantke et al.
EACR-AACR-SIC 2017 Special Conference
Gantke et al.
EACR-AACR-SIC 2017 Special Conference
Kluge et al.
EACR-AACR-SIC 2017 Special Conference
Gantke et al.
ASCO 2017 AFM26
Ellwanger et al.
Front Oncol. 2017 May 19;7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.
Kluge et al.
AACR 2017 – AFM24
Weinschenk et al.
AACR 2017 – MHC
Gantke et al.
AACR 2017 – AFM26
Gantke et al.
ASH 2016 – Trispecific Abs
Düll et al.
ASH 2016 – AFM11
Pahl et al.
ASH 2016 – AFM13